Electrochemical sensor based on Cu_2-xS/graphene heterostructures for sub-picomolar dopamine detection

Area of Science:

• Materials Science
• Electrochemistry
• Nanotechnology

Background:

• Dopamine (DA) detection is crucial for understanding physiological processes like cognition and reward.
• Existing methods for DA detection face challenges in sensitivity, selectivity, and real-world application.
• Graphene and copper sulfide (Cu2-xS) are promising materials for electrochemical sensing applications.

Purpose of the Study:

• To develop a highly sensitive and selective electrochemical sensor for dopamine detection.
• To investigate the properties of a novel Cu2-xS/graphene heterostructure for enhanced electron transfer.
• To evaluate the sensor's performance in biological samples for potential point-of-care diagnostics.

Main Methods:

• Synthesis of p-type Cu2-xS films on p-type graphene/sapphire via chemical vapor deposition and solid-phase sulfurization.
• Optimization of Cu2-xS/graphene heterostructure preparation conditions (temperature, copper film thickness, sulfurization time).
• Electrochemical characterization of the heterostructure and dopamine sensing performance evaluation, including sensitivity, selectivity, and stability tests.

Main Results:

• Optimized Cu2-xS/graphene heterostructure prepared at 250°C exhibited superior electron transfer.
• Spontaneous charge transfer, high Cu(II)/Cu(I) ratio (~0.8), and nanocrystalline Cu2-xS (35 nm) contributed to enhanced performance.
• The sensor achieved a low detection limit of 100 fM for dopamine with a wide dynamic range (>10^9).
• Excellent selectivity was demonstrated against interfering substances like uric and ascorbic acid.
• The sensor successfully detected dopamine at 100 pM in rat serum, showing high stability and repeatability.

Conclusions:

• The Cu2-xS/graphene heterostructure is a highly effective platform for sensitive and selective electrochemical dopamine sensing.
• The sensor's performance characteristics make it suitable for detecting clinically relevant dopamine levels.
• This work presents a promising advancement for point-of-care diagnostic tools in neuroscience and clinical applications.